The Korea Times close
National
  • Politics
  • Diplomacy
  • Defense
  • Labor & Environment
  • Law & Crime
  • Health & Welfare
  • Embassy
  • Seoul & Provinces
  • Education
  • Foreign Communities
  • Obituaries
  • Multicultural Youth Award
Biz & Tech
  • Auto
  • IT
  • Game
  • Manufacturing
  • Retail & Food
  • Energy
  • Construction
  • Airlines
Finance
  • Policies
  • Economy
  • Markets
  • Banks
  • Non-banks
  • Economic Essay Contest
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to the Editor
Lifestyle
  • Arts
  • Books
  • Travel & Cuisine
  • Trend
  • Fashion
  • Around Town
  • Fortune Telling
Entertainment
  • K-pop
  • K-dramas & Shows
  • Movies
  • Music
  • Performances
  • Asia Model Festival
Sports
  • Football
  • Golf
  • Baseball
  • Other Sports
World
  • Asia Pacific
  • Americas
  • Europe & Africa
  • SCMP
Video
  • On the Spot
  • Feature
  • News
Photos
  • Photo News
  • Darkroom
Community
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
Biz & Tech
  • Auto
  • IT
  • Game
  • Manufacturing
  • Retail & Food
  • Energy
  • Construction
  • Airlines
Mon, January 25, 2021 | 05:01
Manufacturing
Samsung wins contract to produce COVID-19 treatments
Posted : 2020-04-10 16:43
Updated : 2020-04-13 01:04
Mail
Print Preview
Font Size Up
Font Size Down
Samsung Biologics' plant 3 in Incheon is seen in this file photo. Courtesy of Samsung BioLogics
Samsung Biologics' plant 3 in Incheon is seen in this file photo. Courtesy of Samsung BioLogics

Pact comes day after President Moon asks South Korea's expanded role to develop COVID-19 vaccines

By Kim Yoo-chul

Samsung Biologics has won $360 million worth of orders for contract production of biopharmaceutical products from a San Francisco-based startup. Under the agreement, the South Korean company will start producing COVID-19 treatment drugs once the U.S. firm completes the development of the drugs.

"Samsung Biologics agreed with Nasdaq-listed Vir Biotechnology to perform large-scale manufacturing services for Vir's SARS-CoV-2 monoclonal antibody (mAb) program. The estimate monetary value of the contract is about $360 million, which is 63 percent out of the total revenue Samsung Biologics reported last year. By volume, the contract is the largest ever since Samsung went public," company spokesman Seo Hae-su said on Friday.

Under the agreement, Samsung Biologics is expected to commence its manufacturing from October this year, at the earliest possible date with the first engineering run, with commercial batches to be manufactured possibly starting in 2021 at Samsung's local plant in Songdo, some 30 kilometers southwest of Seoul.

The Samsung official said both Samsung Biologics and Vir would continue to negotiate additional terms of details in a definitive pact and added the parties will use their "best efforts" to reach a definitive agreement by the end of July.

"We are proud to be working as a partner with Vir in their response to the global COVID-19 pandemic," Samsung Biologics CEO Kim Tae-han said in a released statement. "Vir's candidate molecules supported by Samsung's production scale have the potential to bring hope to countless lives across nations suffering from COVID-19."

Samsung Biologics' plant 3 in Incheon is seen in this file photo. Courtesy of Samsung BioLogics
Samsung Biologics CEO Kim Tae-han
Vir Biotechnology is on track to conduct experimental treatments and potentially vaccines for COVID-19. Vir's lead drugs against the coronavirus, which are monoclonal antibodies, could enter efficacy studies in humans in the next three to five months. Also, the top-tier pharmaceutical company GlaxoSmithKline decided recently to invest up to $250 million in Vir, helping the two encompasses a long-term project to develop a vaccine that might prevent infection from the contagious virus.

Specifically, according to officials, Vir's drugs being pipelined are both based on a single antibody from this patient, and both have been modified to last longer in the body. The company has altered one of the drugs in a bid to create long-term immunity, much like a vaccine. That particular technology has never been tested in humans before, according to them.

Officials and drug experts said antibody drugs could be used in three possible ways ― to prevent people at high risk, such as healthcare workers, from ever becoming infected, to prevent those infected from developing severe respiratory problems that can make COVID-19, the disease caused by the virus, deadly, and to treat people who are already in respiratory distress.

The Samsung-Vir partnership came a day after President Moon Jae-in asked presidential aides, relevant government agencies and private pharmaceutical companies to stand together to develop vaccines and treatments for COVID-19. The Korean leader said the country is ideally positioned to take a lead in developing them.

In a joint meeting with industry, academia, research centers and hospital officials, Thursday, Moon said he is hoping Korea can develop vaccines and relevant medicines that can save human lives, stressing the development of vaccines and drugs is "essential" for putting a complete end to the coronavirus outbreak. The government plans to invest 210 billion won or some $172 million to support vaccine development projects.


Emailyckim@koreatimes.co.kr Article ListMore articles by this reporter









 
WooriBank
 
  • The death of K-pop
  • Tesla vs. Korea
  • 'Hair today, gone tomorrow!' Inventive Russian thrives in Jemulpo
  • First case of pet cat with COVID-19 confirmed in Korea: PM
  • Politicians eating in traditional market raises eyebrows
  • Outback raises prices again to prepare for sale
  • Biden's security team raises hopes for rapid North Korea policy review
  • Companies get aggressive about capital increases
  • Someone in Michigan wins ticket for $1.05 billion jackpot
  • New virus cases under 400 again
  • Hyun Bin thanks Son Ye-jin after winning grand prize at 2020 APAN Star Awards Hyun Bin thanks Son Ye-jin after winning grand prize at 2020 APAN Star Awards
  • Popera singer Lim Hyung-joo: Music is my destiny Popera singer Lim Hyung-joo: Music is my destiny
  • K-pop female artists heat up competition in chart race with comebacks this month K-pop female artists heat up competition in chart race with comebacks this month
  • HyunA to drop new EP, ending yearlong hiatus HyunA to drop new EP, ending yearlong hiatus
  • Larry King, broadcasting giant for half-century, dies after testing positive for COVID-19 Larry King, broadcasting giant for half-century, dies after testing positive for COVID-19
DARKROOM
  • Biden takes office as 46th president

    Biden takes office as 46th president

  • Biden-Harris inauguration is taking shape

    Biden-Harris inauguration is taking shape

  • Second Trump impeachment

    Second Trump impeachment

  • Pro-Trump rioters breach the US Capitol

    Pro-Trump rioters breach the US Capitol

  • Our children deserve better (Part 2)

    Our children deserve better (Part 2)

WooriBank
  • About Korea Times
  • CEO Message
  • Times History
  • Content Sales
  • Media Kit
  • Contact Us
  • Location
  • Privacy Statement
  • Terms of Service
  • Mobile Service
  • RSS Service
  • Ombudsman
  • hankookilbo
  • Dongwha Group
  • Code of Ethics
Copyright